Patents by Inventor Indu Parikh
Indu Parikh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8563689Abstract: The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells in a subject with a chronic inflammatory disease. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.Type: GrantFiled: June 4, 2009Date of Patent: October 22, 2013Assignees: North Carolina State University, Biomarck Pharmaceuticals, Ltd.Inventors: Shuji Takashi, Indu Parikh, Kenneth B. Adler, Linda D. Martin, Yuehua Li
-
Patent number: 8501911Abstract: Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.Type: GrantFiled: August 6, 2007Date of Patent: August 6, 2013Assignees: Biomarck Pharmaceuticals, Ltd, North Carolina State UniversityInventors: Yuehua Li, Linda D. Martin, Kenneth B. Adler, Shuji Takashi, Indu Parikh
-
Patent number: 8492518Abstract: Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.Type: GrantFiled: April 27, 2009Date of Patent: July 23, 2013Assignee: Biomarck Pharmaceuticals Ltd.Inventor: Indu Parikh
-
Patent number: 8293870Abstract: Various methods of using peptides are provided where the peptides comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide.Type: GrantFiled: April 27, 2009Date of Patent: October 23, 2012Assignee: Biomarck Pharmaceuticals LtdInventor: Indu Parikh
-
Patent number: 8206746Abstract: The invention provides a composition comprising microparticles of a water-insoluble or poorly soluble compound, at least one phospholipid, and at least one surfactant, produced by applying an energy to a mixture comprising particles of the compound, the at least one phospholipid, and the at least one surfactant so as to obtain the microparticles. The invention also provides a process for preparing microparticles of a water-insoluble or poorly soluble compound. The process includes mixing particles of a water-insoluble or poorly soluble compound with at least one phospholipid and at least surfactant to form a mixture and applying energy to the mixture sufficient to produce microparticles of the compound. The methods of the invention allow for the production of microparticles smaller than particles produced through previously known methods and the microparticles exhibit advantageous properties including remarkable resistance to particle size growth during storage.Type: GrantFiled: September 30, 2002Date of Patent: June 26, 2012Assignee: Jagotec AGInventors: Indu Parikh, Ulagaraj Selvaraj
-
Publication number: 20120064160Abstract: This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.Type: ApplicationFiled: November 14, 2011Publication date: March 15, 2012Applicant: Jagotec AGInventors: Pol-Henri Guivarc'h, Indu Parikh, Robert A. Snow
-
Publication number: 20110244032Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: ApplicationFiled: May 10, 2011Publication date: October 6, 2011Applicant: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7939106Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: May 23, 2003Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7939105Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: November 19, 1999Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Publication number: 20100197607Abstract: Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.Type: ApplicationFiled: April 27, 2009Publication date: August 5, 2010Inventor: Indu PARIKH
-
Publication number: 20090275520Abstract: Various methods of using peptides are provided where the peptides comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide.Type: ApplicationFiled: April 27, 2009Publication date: November 5, 2009Inventor: Indu PARIKH
-
Publication number: 20090220581Abstract: Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.Type: ApplicationFiled: August 6, 2007Publication date: September 3, 2009Inventors: Yuehua LI, Linda D. Martin, Kenneth B. Adler, Shuji Takashi, Indu Parikh
-
Publication number: 20090203620Abstract: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.Type: ApplicationFiled: January 26, 2009Publication date: August 13, 2009Inventor: Indu PARIKH
-
Patent number: 7544772Abstract: The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.Type: GrantFiled: March 6, 2006Date of Patent: June 9, 2009Assignee: Biomarck Pharmaceuticals, Ltd.Inventors: Shuji Takashi, Indu Parikh, Kenneth B. Adler, Linda D. Martin, Yuehua Li
-
Patent number: 7524926Abstract: Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.Type: GrantFiled: January 20, 2006Date of Patent: April 28, 2009Assignee: Biomarck Pharmaceuticals, Ltd.Inventor: Indu Parikh
-
Publication number: 20090041731Abstract: Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-?, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-? gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand.Type: ApplicationFiled: June 10, 2008Publication date: February 12, 2009Inventors: Indu Parikh, Anne Lane, Ronald V. Nardi, Stephen J. Brand
-
Patent number: 7255877Abstract: Fenofibrate microparticles are prepared using a combination of surface modifiers with a phospholipid. Particle size growth and stability are controlled while significantly smaller sized fenofibrate particles are produced.Type: GrantFiled: March 31, 1999Date of Patent: August 14, 2007Assignee: Jagotec AGInventor: Indu Parikh
-
Publication number: 20060217307Abstract: The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.Type: ApplicationFiled: March 6, 2006Publication date: September 28, 2006Inventors: Shuji Takashi, Indu Parikh, Kenneth Adler, Linda Martin, Yuehua Li
-
Publication number: 20060205664Abstract: Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.Type: ApplicationFiled: January 20, 2006Publication date: September 14, 2006Inventor: Indu Parikh
-
Patent number: 6979456Abstract: Pharmaceutical dosage forms for anticancer drugs, and paclitaxel in particular, are described in which the active drug is formulated as storage stable self-emulsifying preconcentrate.Type: GrantFiled: March 30, 1999Date of Patent: December 27, 2005Assignee: Jagotec AGInventors: Indu Parikh, Iskandar Moussa, Alain Carrier